APYXHealthcare · Medical DevicesThe 5 Wall Street analysts covering Apyx Medical Corp. hold a median 12-month price target of $6 — +43.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 85 of 100 as at 1 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Apyx Medical Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (95): Sales and profits are climbing, and climbing faster than before.
Issuance (28): The company has been issuing shares or taking on financing, diluting existing holders.
The rank is the raw material. Whether the rules would actually own Apyx Medical Corp. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on APYX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +43.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 July 2026 | HC Wainwright & Co. | Initiates | Buy | $7.00 |
| 11 Mar 2026 | BTIG | Upgrade | Buy | — |
| 11 Mar 2026 | Craig-Hallum | Maintains | Buy | — |
| 16 Dec 2025 | Roth Capital | Initiates | Buy | — |
| 12 Nov 2025 | Citizens | Upgrade | Market Outperform | — |
| 17 Oct 2024 | BTIG | Initiates | Neutral | — |
| 16 Sept 2024 | JMP Securities | Reiterates | Market Perform | — |
| 10 Nov 2023 | Stephens & Co. | Maintains | Overweight | — |
| 11 Aug 2023 | Piper Sandler | Maintains | Overweight | — |
| 14 July 2023 | Stephens & Co. | Initiates | Overweight | — |
| 15 June 2023 | Lake Street | Maintains | Buy | — |
| 24 May 2023 | JMP Securities | Reiterates | Market Perform | — |
| 12 May 2023 | Lake Street | Maintains | Buy | — |
| 8 Dec 2022 | Lake Street | Assumes | Buy | $5.00 |
| 12 Aug 2022 | Piper Sandler | Maintains | Overweight | — |
| 19 July 2022 | Lake Street | Maintains | Buy | — |
| 20 May 2022 | Lake Street | Initiates | Buy | — |
| 13 Aug 2021 | JMP Securities | Maintains | Market Outperform | — |
| 12 May 2020 | JMP Securities | Maintains | Market Outperform | — |
| 12 Nov 2019 | Piper Jaffray | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 95% of US stocks
Cheaper than 41% of US stocks
Cheaper than 8% of US stocks
Cheaper than 94% of US stocks
Higher than 81% of US stocks
Higher than 70% of US stocks
Higher than 78% of US stocks
Higher than 28% of US stocks
Higher than 17% of US stocks
Higher than 16% of US stocks
Higher than 33% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. APYX appears on the weeks it earns a place.
Apyx Medical Corporation announced that its management will participate in the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026, in Boston, MA.
Why it matters — The company's participation in this investor conference provides an opportunity for management to present the business to the financial community.
The 5 Wall Street analysts covering Apyx Medical Corp. have a median 12-month price target of $6, with estimates ranging from $6 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering Apyx Medical Corp., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Apyx Medical Corp. 85 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, Apyx Medical Corp. ranks 85 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (95 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +43.5% from the last close, and Ticker Nerd's factor model ranks Apyx Medical Corp. 85 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Apyx Medical Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for APYX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $8 over the next 12 months.
Apyx Medical Corp. returned +138.9% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Apyx Medical Corporation is an advanced energy technology company specializing in the design, development, and manufacturing of electrosurgical equipment and medical devices. The company is best known for its proprietary helium plasma technology, marketed as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market, which enables surgeons to precisely cut, coagulate, and ablate soft tissue during both open and minimally invasive procedures.
The most recent item we track (GlobeNewsWire, 28 July 2026): "Apyx Medical Corporation to Participate in the Canaccord Genuity 46th Annual Growth Conference". Apyx Medical Corporation announced that its management will participate in the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026, in Boston, MA.
Apyx Medical Corporation is an advanced energy technology company specializing in the design, development, and manufacturing of electrosurgical equipment and medical devices. The company is best known for its proprietary helium plasma technology, marketed as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market, which enables surgeons to precisely cut, coagulate, and ablate soft tissue during both open and minimally invasive procedures. Apyx Medical also produces the AYON Body Contouring System, an all-in-one platform for body contouring that integrates advanced modalities for fat removal, tissue contraction, and aesthetic enhancement. In addition to its own branded products, the company leverages its expertise in unique waveforms through original equipment manufacturing (OEM) agreements with other medical device manufacturers. Headquartered in Clearwater, Florida, Apyx Medical serves both domestic and international markets, supporting physicians and patients with innovative solutions that elevate surgical outcomes and patient care.
CEO Mr. Charles D. Goodwin II · 205 employees · United States · https://apyxmedical.com